Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for COSENTYX
- Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx in Healthy Male Subjects
- Outcome of Treatment With Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis at Tertiary Care Hospital.
- A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 4
- Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients
- A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis
- COVID-19 VaccinE Response in Rheumatology Patients
- Comparative Study to Evaluate the Pharmacokinetics of BAT2306 vs Cosentyx® in Healthy Subjects
- Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis
- A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 1
- Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)
- Oral Chinese Herbal Medicine Concurrent With Secukinumab for Severe Plaque Psoriasis
- Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis
- A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus
- Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)
- Personalized Therapies in Inflammatory Complex Disease
- PsA Secukinumab XCT Structural Progression Study
- Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis
- Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis
- Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome
- Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris
- Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT).
- Safety and Efficacy of Secukinumab in Mild Psoriasis
- A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
- The Efficacy and Safety of Secukinumab in Patients With Ichthyoses
- Effect of Secukinumab in the Treatment of Psoriatic Arthritis
- Anti-IL-17 a New Treatment for Contact Dermatititis
- Immunologic Response to Secukinumab in Plaque Psoriasis
- Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis
Clinical trials list
click for details